# A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD

> **NCT06205095** · PHASE3 · RECRUITING · sponsor: **Unity Health Toronto** · enrollment: 20 (estimated)

## Conditions studied

- Von Willebrand Diseases

## Interventions

- **DRUG:** Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06205095
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205095, "A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06205095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*